BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wall SA, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, Yang S, Wu H, Bostic M, Jaglowski S, Brammer JE, William B, Choe H, Mims AS, Penza S, Efebera Y, Devine S, Cataland S, Davies SM, Vasu S. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. Blood Adv. 2018;2:2619-2628. [PMID: 30327370 DOI: 10.1182/bloodadvances.2018020321] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Heja D, Zhao D, Cody E, Cumpelik A, Lim PC, Prado-acosta M, Palma L, Dellepiane S, Chun N, Ferrara J, Heeger PS. Mannan binding lectin promotes murine graft versus host disease by amplifying lipopolysaccharide-initiated inflammation. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.05.031] [Reference Citation Analysis]
2 Dubouchet L, Todorov H, Seurinck R, Vallet N, Van Gassen S, Corneau A, Blanc C, Zouali H, Boland A, Deleuze JF, Ingram B, de Latour RP, Saeys Y, Socié G, Michonneau D. Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures. Sci Transl Med 2022;14:eabg3083. [PMID: 35196024 DOI: 10.1126/scitranslmed.abg3083] [Reference Citation Analysis]
3 Okamura H, Nakamae H, Shindo T, Ohtani K, Hidaka Y, Ohtsuka Y, Makuuchi Y, Kuno M, Takakuwa T, Harada N, Nishimoto M, Nakashima Y, Koh H, Hirose A, Nakamae M, Wakamiya N, Hino M, Inoue N. Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy. Front Immunol 2021;12:695037. [PMID: 34326846 DOI: 10.3389/fimmu.2021.695037] [Reference Citation Analysis]
4 Kaya AH, Tekgunduz E. Management of thrombotic microangiopathy after hematopoietic cell transplantation: A position statement of ThREG (Turkish Hematology Research and Education Group). Transfus Apher Sci 2021;:103313. [PMID: 34785151 DOI: 10.1016/j.transci.2021.103313] [Reference Citation Analysis]
5 Gavriilaki E, Ho VT, Schwaeble W, Dudler T, Daha M, Fujita T, Jodele S. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol 2021;10:57. [PMID: 34924021 DOI: 10.1186/s40164-021-00249-8] [Reference Citation Analysis]
6 Hong YQ, Wan B, Li XF. Macrophage regulation of graft-vs-host disease. World J Clin Cases 2020; 8(10): 1793-1805 [PMID: 32518770 DOI: 10.12998/wjcc.v8.i10.1793] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
7 Dandoy CE, Rotz S, Alonso PB, Klunk A, Desmond C, Huber J, Ingraham H, Higham C, Dvorak CC, Duncan C, Schoettler M, Lehmann L, Cancio M, Killinger J, Davila B, Phelan R, Mahadeo KM, Khazal S, Lalefar N, Vissa M, Myers K, Wallace G, Nelson A, Khandelwal P, Bhatla D, Gloude N, Anderson E, Huo J, Roehrs P, Auletta JJ, Chima R, Lane A, Davies SM, Jodele S. A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Adv 2021;5:1-11. [PMID: 33570619 DOI: 10.1182/bloodadvances.2020003455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Dhaliwal M, Tyagi R, Malhotra P, Barman P, Loganathan SK, Sharma J, Sharma K, Mondal S, Rawat A, Singh S. Mechanisms of Immune Dysregulation in COVID-19 Are Different From SARS and MERS: A Perspective in Context of Kawasaki Disease and MIS-C. Front Pediatr 2022;10:790273. [DOI: 10.3389/fped.2022.790273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Diorio C, Henrickson SE, Vella LA, McNerney KO, Chase J, Burudpakdee C, Lee JH, Jasen C, Balamuth F, Barrett DM, Banwell BL, Bernt KM, Blatz AM, Chiotos K, Fisher BT, Fitzgerald JC, Gerber JS, Gollomp K, Gray C, Grupp SA, Harris RM, Kilbaugh TJ, John ARO, Lambert M, Liebling EJ, Paessler ME, Petrosa W, Phillips C, Reilly AF, Romberg ND, Seif A, Sesok-Pizzini DA, Sullivan KE, Vardaro J, Behrens EM, Teachey DT, Bassiri H. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest 2020;130:5967-75. [PMID: 32730233 DOI: 10.1172/JCI140970] [Cited by in Crossref: 106] [Cited by in F6Publishing: 79] [Article Influence: 53.0] [Reference Citation Analysis]
10 Imus PH, Tsai HL, DeZern AE, Jerde K, Swinnen LJ, Bolaños-Meade J, Luznik L, Fuchs EJ, Wagner-Johnston N, Huff CA, Gladstone DE, Ambinder RF, Gocke CB, Ali SA, Borrello IM, Varadhan R, Brodsky R, Jones RJ. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 2020;26:2306-10. [PMID: 32961372 DOI: 10.1016/j.bbmt.2020.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Jodele S, Sabulski A. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients. Expert Rev Hematol 2021;14:751-63. [PMID: 34301169 DOI: 10.1080/17474086.2021.1960816] [Reference Citation Analysis]
12 Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 2020;135:1049-57. [PMID: 31932840 DOI: 10.1182/blood.2019004218] [Cited by in Crossref: 14] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
13 Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R, Kordelas L, Beelen D, Gooley T, Sandmaier BM, Sorror M, Zeisbrich M, Radujkovic A, Dreger P, Penack O. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2020;55:553-61. [PMID: 31558788 DOI: 10.1038/s41409-019-0703-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
14 Elfeky R, Lucchini G, Lum SH, Ottaviano G, Builes N, Nademi Z, Battersby A, Flood T, Owens S, Cant AJ, Young H, Greener S, Walsh P, Kavanagh D, Annavarapu S, Rao K, Amrolia P, Chiesa R, Worth A, Booth C, Skinner R, Doncheva B, Standing J, Gennery AR, Qasim W, Slatter M, Veys P. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. Blood Adv 2020;4:2418-29. [PMID: 32492158 DOI: 10.1182/bloodadvances.2019001315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Ehmann MA, Medinger M, Bodenmann B, Kraft S, Bollinger N, Heim D, Lengerke C, Tsakiris DA, Passweg J, Tzankov A, Menter T. Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best percepted in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host disease in gastrointestinal biopsies. Bone Marrow Transplant 2020;55:1847-50. [PMID: 32231248 DOI: 10.1038/s41409-020-0880-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Martin PJ. How I treat steroid-refractory acute graft-versus-host disease. Blood 2020;135:1630-8. [PMID: 32202630 DOI: 10.1182/blood.2019000960] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
17 Zhang R, Zhou M, Qi J, Miao W, Zhang Z, Wu D, Han Y. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Front Immunol 2020;11:564647. [PMID: 33552043 DOI: 10.3389/fimmu.2020.564647] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Matsui H, Arai Y, Imoto H, Mitsuyoshi T, Tamura N, Kondo T, Kanda J, Ishikawa T, Imada K, Ueda Y, Toda Y, Anzai N, Yago K, Nohgawa M, Yonezawa A, Tsunemine H, Itoh M, Yamamoto K, Tsuji M, Moriguchi T, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Adv 2020;4:3169-79. [PMID: 32658984 DOI: 10.1182/bloodadvances.2020002007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
19 Scordo M, Giralt S. Compliments to complement blockade for TA-TMA. Blood 2020;135:981-3. [PMID: 32219351 DOI: 10.1182/blood.2020005040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Meri S, Bunjes D, Cofiell R, Jodele S. The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice. Adv Ther 2022. [PMID: 35781192 DOI: 10.1007/s12325-022-02184-4] [Reference Citation Analysis]
21 Elhadad S, Chadburn A, Magro C, Van Besien K, Roberson EDO, Atkinson JP, Terry H, Greenberg J, Reid W, Chapin J, Copertino D, Geramfard S, Rodriguez LB, Orfali N, Gerghis U, Shore T, Mayer S, Ahamed J, Laurence J. C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. [DOI: 10.1038/s41409-022-01723-5] [Reference Citation Analysis]
22 Holtan SG, Shabaneh A, Betts BC, Rashidi A, MacMillan ML, Ustun C, Amin K, Vaughn BP, Howard J, Khoruts A, Arora M, DeFor TE, Johnson D, Blazar BR, Weisdorf DJ, Wang J. Stress Responses, M2 Macrophages, and a Distinct Microbial Signature in Fatal Intestinal Acute Graft-Versus-Host Disease. JCI Insight. 2019;5:e129762. [PMID: 31393854 DOI: 10.1172/jci.insight.129762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
23 Toubai T, Magenau J. Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease. Blood 2020;136:429-40. [PMID: 32526035 DOI: 10.1182/blood.2019000953] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
24 Gavriilaki E, Sakellari I, Karafoulidou I, Pasteli N, Batsis I, Mallouri D, Lazaridou A, Iskas M, Vardi A, Papalexandri A, Tsompanakou A, Papaemmanouil S, Ilias A, Anagnostopoulos A. Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease. Int J Hematol 2019;110:529-32. [PMID: 31586304 DOI: 10.1007/s12185-019-02750-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
25 Scordo M, Giralt SA. A key step towards setting a benchmark for tackling transplant‐associated thrombotic microangiopathy. Br J Haematol 2020;189:1006-9. [DOI: 10.1111/bjh.16507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Choe H, Ferrara JLM. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD). Expert Opin Ther Targets 2021;25:761-71. [PMID: 34669521 DOI: 10.1080/14728222.2021.1992383] [Reference Citation Analysis]
27 Mariotti J, Penack O, Castagna L. Acute Graft-versus-Host-Disease Other Than Typical Targets: Between Myths and Facts.Transplant Cell Ther. 2021;27:115-124. [PMID: 33017661 DOI: 10.1016/j.bbmt.2020.09.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Campbell CM, Guha A, Haque T, Neilan TG, Addison D. Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review. J Clin Med 2020;9:E2935. [PMID: 32932930 DOI: 10.3390/jcm9092935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
29 Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol 2020;189:1171-81. [PMID: 32124435 DOI: 10.1111/bjh.16457] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
30 Holtan SG, Versluis J, Weisdorf DJ, Cornelissen JJ. Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. J Clin Oncol 2021;39:373-85. [PMID: 33434075 DOI: 10.1200/JCO.20.01771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
31 Li A, Bhatraju PK, Chen J, Chung DW, Hilton T, Houck K, Pao E, Weiss NS, Lee SJ, Davis C, Schmidt MJ, Lopez JA, Liles WC, Dong JF, Hingorani SR. Prognostic Biomarkers for Thrombotic Microangiopathy after Acute Graft-versus-Host Disease: A Nested Case-Control Study. Transplant Cell Ther 2021;27:308.e1-8. [PMID: 33836868 DOI: 10.1016/j.jtct.2020.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Jodele S, Medvedovic M, Luebbering N, Chen J, Dandoy CE, Laskin BL, Davies SM. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv 2020;4:1166-77. [PMID: 32208488 DOI: 10.1182/bloodadvances.2020001515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]